Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest National Institute of Neurological Disorders and Stroke Stories

2011-09-06 06:00:00

LOS ANGELES, Sept. 6, 2011 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disorders and Stroke (NINDS). This will support further development of external trigeminal nerve stimulation (eTNS(TM)) therapy for the treatment of drug-resistant epilepsy, for which NeuroSigma is the exclusive worldwide...

2011-08-25 14:51:30

Preliminary NIH study may have implications for early onset of the disease National Institutes of Health researchers have found that Parkin, an important protein linked with some cases of early-onset Parkinson's disease, regulates how cells in our bodies take up and process dietary fats. Parkinson's disease is a complex, progressive, and currently incurable neurological disorder characterized by shaking, stiffness, slowed movement, and impaired balance. Parkinson's primarily affects...

2011-05-03 08:00:00

ANN ARBOR, Mich., May 3, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that after scientific review, the ongoing clinical trial of its Trimesta(TM) (oral estriol) drug candidate for multiple sclerosis (MS) has received an additional $1,594,553 in grant funding from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS). The clinical...

2011-03-01 08:00:00

HOBOKEN, NJ, March 1 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of Dr. Jeffrey Cummings to the Scientific Advisory Board as a clinical expert.  The Scientific Advisory Board works closely with the company to support development of the Anavex product pipeline, including its lead compound ANAVEX 2-73, which is being studied for Alzheimer's disease and is scheduled to enter Phase I clinical trials shortly.  Dr....

2011-01-25 05:30:00

SAN DIEGO, Jan. 25, 2011 /PRNewswire/ -- AndroScience Corp. (ASC), based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). Through a joint research effort with the Neurogenetics Branch of the NINDS, ASC will use the funding to pursue development of an oral drug treatment for spinal and bulbar...

7a3c99eaa85c90857a8a7a3e4e33ec861
2010-10-27 13:55:00

Move over, touchpad screens: New research funded in part by the National Institutes of Health shows that it is possible to manipulate complex visual images on a computer screen using only the mind. The study, published in Nature, found that when research subjects had their brains connected to a computer displaying two merged images, they could force the computer to display one of the images and discard the other. The signals transmitted from each subject's brain to the computer were derived...

ea1ef96bd4a6f645ddbaf9ba9ccdba981
2010-10-19 10:35:00

Repeated exposure to violent television programs and video games can make teenage boys behave more aggressively, according to a new study published online today in the journal Social Cognitive and Affective Neuroscience. According to a press release, Dr. Jordan Grafman and colleagues at the National Institutes of Health's (NIH) National Institute of Neurological Disorders and Stroke recruited 22 14- to 17-year-olds and showed each of them a series of violent clips. The footage used was...

2010-09-08 11:32:00

WEST ORANGE, N.J., Sept. 8 /PRNewswire/ -- Kessler Foundation announced that Jordan Grafman, Ph.D., will join Kessler Foundation Research Center as Director of the Traumatic Brain Injury (TBI) Research Laboratory. He will assume his position on January 3, 2011. President and Chief Executive Officer of Kessler Foundation, Rodger DeRose, said, "We're very excited to have Dr. Grafman lead Kessler Foundation's TBI research team. With his decades of national leadership, depth of expertise in...

2010-09-03 07:47:00

$11 Million Supports Five-Year Study to Compare Treatments ROCHESTER, N.Y., Sept. 3 /PRNewswire-USNewswire/ -- A large international study aimed at improving the care of muscular dystrophy patients worldwide is being launched by physicians, physical therapists, and researchers at the University of Rochester Medical Center. Neurologist Robert "Berch" Griggs, M.D., is heading the study of treatments for Duchenne muscular dystrophy, the most common form of the disease that affects children....

2010-08-02 07:49:00

WALTHAM, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase (HDAC) inhibitors for Friedreich's ataxia. The funding is comprised of $218,000 from the Friedreich's Ataxia Research Alliance (FARA) and...